BACKGROUND: Since 2006, more than 100 countries have introduced rotavirus vaccine into their immunization programs. We reviewed published data on relative reductions of rotavirus hospitalizations, acute gastroenteritis (AGE) hospitalizations, and AGE deaths among children <5 years old. METHODS: Articles published from January 1, 2006 to December 31, 2019 with at least 12 months of data before and after rotavirus vaccine introduction were included. Relative reductions were abstracted into a standardized form. Descriptive statistics are presented as medians and interquartile ranges (IQRs). RESULTS: We reviewed 1827 total records and included 105 articles from 49 countries. Among children <5 years old, there was a median reduction of 59% (IQR, 46-74) in rotavirus hospitalizations, 36% (IQR, 23-47) in AGE hospitalizations, and 36% (IQR, 28-46) AGE mortality. Reductions were larger in countries with low child mortality, among younger age groups, and in countries with higher coverage. The median percentage of specimens that tested positive for rotavirus among children <5 years old hospitalized for diarrhea was 40% (IQR, 28-45) before rotavirus vaccine introduction and 20% (IQR, 20-20) 4 years after introduction. CONCLUSIONS: Overall, we found sustained impact on rotavirus and AGE hospitalizations and deaths. These results should encourage countries still considering rotavirus vaccine implementation. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: Since 2006, more than 100 countries have introduced rotavirus vaccine into their immunization programs. We reviewed published data on relative reductions of rotavirus hospitalizations, acute gastroenteritis (AGE) hospitalizations, and AGEdeaths among children <5 years old. METHODS: Articles published from January 1, 2006 to December 31, 2019 with at least 12 months of data before and after rotavirus vaccine introduction were included. Relative reductions were abstracted into a standardized form. Descriptive statistics are presented as medians and interquartile ranges (IQRs). RESULTS: We reviewed 1827 total records and included 105 articles from 49 countries. Among children <5 years old, there was a median reduction of 59% (IQR, 46-74) in rotavirus hospitalizations, 36% (IQR, 23-47) in AGE hospitalizations, and 36% (IQR, 28-46) AGEmortality. Reductions were larger in countries with low childmortality, among younger age groups, and in countries with higher coverage. The median percentage of specimens that tested positive for rotavirus among children <5 years old hospitalized for diarrhea was 40% (IQR, 28-45) before rotavirus vaccine introduction and 20% (IQR, 20-20) 4 years after introduction. CONCLUSIONS: Overall, we found sustained impact on rotavirus and AGE hospitalizations and deaths. These results should encourage countries still considering rotavirus vaccine implementation. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Entities:
Keywords:
acute gastroenteritis; impact; literature review; rotavirus; rotavirus vaccine
Authors: Evan J Anderson; Deanna B Shippee; Melissa H Weinrobe; Melissa D Davila; Ben Z Katz; Susheel Reddy; Mary Gene Karen P Cuyugan; Samuel Y Lee; Yael M Simons; Ram Yogev; Gary A Noskin Journal: Clin Infect Dis Date: 2013-01-23 Impact factor: 9.079
Authors: Eleanor Burnett; Jacqueline E Tate; Carl D Kirkwood; E Anthony S Nelson; Mathuram Santosham; A Duncan Steele; Umesh D Parashar Journal: Expert Rev Vaccines Date: 2018-02-26 Impact factor: 5.217
Authors: Christina J Atchison; Julia Stowe; Nick Andrews; Sarah Collins; David J Allen; Sameena Nawaz; David Brown; Mary E Ramsay; Shamez N Ladhani Journal: J Infect Dis Date: 2015-07-30 Impact factor: 5.226
Authors: Sarah E Wilson; Laura C Rosella; Jun Wang; Nicole Le Saux; Natasha S Crowcroft; Tara Harris; Shelly Bolotin; Shelley L Deeks Journal: PLoS One Date: 2016-05-11 Impact factor: 3.240
Authors: Negar Aliabadi; Sébastien Antoni; Jason M Mwenda; Goitom Weldegebriel; Joseph N M Biey; Dah Cheikh; Kamal Fahmy; Nadia Teleb; Hossam Abdelrahman Ashmony; Hinda Ahmed; Danni S Daniels; Dovile Videbaek; Annemarie Wasley; Simarjit Singh; Lucia Helena de Oliveira; Gloria Rey-Benito; N Jennifer Sanwogou; Pushpa Ranjan Wijesinghe; Jayantha B L Liyanage; Batmunkh Nyambat; Varja Grabovac; James D Heffelfinger; Kimberley Fox; Fem Julia Paladin; Tomoka Nakamura; Mary Agócs; Jillian Murray; Thomas Cherian; Catherine Yen; Umesh D Parashar; Fatima Serhan; Jacqueline E Tate; Adam L Cohen Journal: Lancet Glob Health Date: 2019-07 Impact factor: 26.763
Authors: Daniel Hungerford; Roberto Vivancos; Jonathan M Read; Miren Iturriza-Gόmara; Neil French; Nigel A Cunliffe Journal: BMC Med Date: 2018-01-29 Impact factor: 8.775
Authors: Liliana Sánchez-Tacuba; Ningguo Feng; Nathan J Meade; Kenneth H Mellits; Philippe H Jaïs; Linda L Yasukawa; Theresa K Resch; Baoming Jiang; Susana López; Siyuan Ding; Harry B Greenberg Journal: J Virol Date: 2020-08-31 Impact factor: 5.103
Authors: Jordan E Cates; Avnika B Amin; Jacqueline E Tate; Ben Lopman; Umesh Parashar Journal: Pediatr Infect Dis J Date: 2021-12-01 Impact factor: 2.129
Authors: F Amadori; E Terracciano; I Gennaio; V Mita; D Gargano; L Zaratti; E Franco; R Arigliani Journal: Hum Vaccin Immunother Date: 2020-07-02 Impact factor: 3.452